
Thomas Beyer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6371335/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 328-354.	6.4	2,188
2	FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 181-200.	6.4	1,147
3	A combined PET/CT scanner for clinical oncology. Journal of Nuclear Medicine, 2000, 41, 1369-79.	5.0	1,022
4	Attenuation correction for a combined 3D PET/CT scanner. Medical Physics, 1998, 25, 2046-2053.	3.0	766
5	Non–Small Cell Lung Cancer: Dual-Modality PET/CT in Preoperative Staging. Radiology, 2003, 229, 526-533.	7.3	525
6	X-ray-based attenuation correction for positron emission tomography/computed tomography scanners. Seminars in Nuclear Medicine, 2003, 33, 166-179.	4.6	448
7	Accuracy of Whole-Body Dual-Modality Fluorine-18–2-Fluoro-2-Deoxy- <scp>d</scp> -Glucose Positron Emission Tomography and Computed Tomography (FDG-PET/CT) for Tumor Staging in Solid Tumors: Comparison With CT and PET. Journal of Clinical Oncology, 2004, 22, 4357-4368.	1.6	424
8	Towards quantitative PET/MRI: a review of MR-based attenuation correction techniques. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 93-104.	6.4	314
9	Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. Journal of Nuclear Medicine, 2005, 46, 608-13.	5.0	298
10	Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 588-596.	6.4	274
11	MRI-Based Attenuation Correction for Whole-Body PET/MRI: Quantitative Evaluation of Segmentation- and Atlas-Based Methods. Journal of Nuclear Medicine, 2011, 52, 1392-1399.	5.0	255
12	FDG-PET/CT in re-staging of patients with lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 325-329.	6.4	226
13	PET/CT scanners: A hardware approach to image fusion. Seminars in Nuclear Medicine, 2003, 33, 193-204.	4.6	224
14	Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage. Journal of Immunology, 2010, 184, 512-520.	0.8	219
15	Clinically feasible reconstruction of 3D whole-body PET/CT data using blurred anatomical labels. Physics in Medicine and Biology, 2002, 47, 1-20.	3.0	208
16	A combined PET/CT scanner: the path to true image fusion. British Journal of Radiology, 2002, 75, S24-S30.	2.2	197
17	Combined PET/MR imaging in neurology: MR-based attenuation correction implies a strong spatial bias when ignoring bone. NeuroImage, 2014, 84, 206-216.	4.2	170
18	Image Analysis in Patients with Cancer Studied with a Combined PET and CT Scanner. Clinical Nuclear Medicine, 2000, 25, 905-910.	1.3	142

#	Article	IF	CITATIONS
19	Dual-Modality PET/CT Scanning with Negative Oral Contrast Agent to Avoid Artifacts: Introduction and Evaluation. Radiology, 2004, 230, 879-885.	7.3	141
20	Positron emission tomography/computed tomography?imaging protocols, artifacts, and pitfalls. Molecular Imaging and Biology, 2004, 6, 188-199.	2.6	125
21	Variations in Clinical PET/CT Operations: Results of an International Survey of Active PET/CT Users. Journal of Nuclear Medicine, 2011, 52, 303-310.	5.0	119
22	Image artifacts from MR-based attenuation correction in clinical, whole-body PET/MRI. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2013, 26, 173-181.	2.0	119
23	Performance Evaluation of the Vereos PET/CT System According to the NEMA NU2-2012 Standard. Journal of Nuclear Medicine, 2019, 60, 561-567.	5.0	117
24	Performance evaluation of the Biograph mCT Flow PET/CT system according to the NEMA NU2-2012 standard. EJNMMI Physics, 2015, 2, 26.	2.7	99
25	MR-based attenuation correction for torso-PET/MR imaging: pitfalls in mapping MR to CT data. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1142-1146.	6.4	98
26	PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 51-60.	6.4	98
27	Glioma Survival Prediction with Combined Analysis of In Vivo ¹¹ C-MET PET Features, Ex Vivo Features, and Patient Features by Supervised Machine Learning. Journal of Nuclear Medicine, 2018, 59, 892-899.	5.0	94
28	Effector Mechanisms of Recombinant IgA Antibodies against Epidermal Growth Factor Receptor. Journal of Immunology, 2007, 179, 2936-2943.	0.8	91
29	The effect of MR surface coils on PET quantification in whole-body PET/MR: Results from a pseudo-PET/MR phantom study. Medical Physics, 2011, 38, 2795-2805.	3.0	76
30	Simultaneous 68Ga-DOTATOC-PET/MRI for IMRT Treatment Planning for Meningioma: First Experience. International Journal of Radiation Oncology Biology Physics, 2011, 81, 277-283.	0.8	75
31	Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [68Ga]Ga-PSMA-11 PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1795-1805.	6.4	72
32	TNM staging with FDG-PET/CT in patients with primary head and neck cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1953-1962.	6.4	70
33	To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. Journal of Nuclear Medicine, 2004, 45 Suppl 1, 56S-65S.	5.0	66
34	Whole-body PET/MRI: The effect of bone attenuation during MR-based attenuation correction in oncology imaging. European Journal of Radiology, 2014, 83, 1177-1183.	2.6	65
35	Recombinant Dimeric IgA Antibodies against the Epidermal Growth Factor Receptor Mediate Effective Tumor Cell Killing. Journal of Immunology, 2011, 186, 3770-3778.	0.8	62
36	Investigating the state-of-the-art in whole-body MR-based attenuation correction: an intra-individual, inter-system, inventory study on three clinical PET/MR systems. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2016, 29, 75-87.	2.0	62

#	Article	IF	CITATIONS
37	Optimized intravenous contrast administration for diagnostic whole-body 18F-FDG PET/CT. Journal of Nuclear Medicine, 2005, 46, 429-35.	5.0	60
38	Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 910-918.	6.4	59
39	Respiration artifacts in whole-body 18F-FDG PET/CT studies with combined PET/CT tomographs employing spiral CT technology with 1 to 16 detector rows. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1429-1439.	6.4	56
40	A decade of combined imaging: from a PET attached to a CT to a PET inside an MR. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1-2.	6.4	56
41	Combined PET/MRI: Multi-modality Multi-parametric Imaging Is Here. Molecular Imaging and Biology, 2015, 17, 595-608.	2.6	56
42	Acquisition protocol considerations for combined PET/CT imaging. Journal of Nuclear Medicine, 2004, 45 Suppl 1, 25S-35S.	5.0	56
43	Clinical evaluation of PET image reconstruction using a spatial resolution model. European Journal of Radiology, 2013, 82, 862-869.	2.6	55
44	Whole-body 18F-FDG PET/CT in the presence of truncation artifacts. Journal of Nuclear Medicine, 2006, 47, 91-9.	5.0	54
45	The SMART scanner: a combined PET/CT tomograph for clinical oncology. , 0, , .		53
46	Whole-body hybrid PET/MRI: ready for clinical use?. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 992-995.	6.4	53
47	The future of hybrid imaging—part 3: PET/MR, small-animal imaging and beyond. Insights Into Imaging, 2011, 2, 235-246.	3.4	53
48	Integration of FDG- PET/CT into external beam radiation therapy planning. Nuklearmedizin - NuclearMedicine, 2012, 51, 140-153.	0.7	52
49	Time-of-flight PET/CT using low-activity protocols: potential implications for cancer therapy monitoring. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1643-1653.	6.4	51
50	The future of hybrid imaging—part 2: PET/CT. Insights Into Imaging, 2011, 2, 225-234.	3.4	51
51	Quality control for quantitative multicenter wholeâ€body PET/MR studies: A NEMA image quality phantom study with three current PET/MR systems. Medical Physics, 2015, 42, 5961-5969.	3.0	51
52	PET/CT for the assessment and quantification of 90Y biodistribution after selective internal radiotherapy (SIRT) of liver metastases. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 407-408.	6.4	50
53	Subjective Perception of Radiation Risk. Journal of Nuclear Medicine, 2011, 52, 29S-35S.	5.0	49
54	Serum-free production and purification of chimeric IgA antibodies. Journal of Immunological Methods, 2009, 346, 26-37.	1.4	47

#	Article	IF	CITATIONS
55	Optimized Feature Extraction for Radiomics Analysis of ¹⁸ F-FDG PET Imaging. Journal of Nuclear Medicine, 2019, 60, 864-872.	5.0	46
56	Dual-modality PET/CT instrumentation—Today and tomorrow. European Journal of Radiology, 2010, 73, 452-460.	2.6	45
57	Characterization of a Mutated IgA2 Antibody of the m(1) Allotype against the Epidermal Growth Factor Receptor for the Recruitment of Monocytes and Macrophages. Journal of Biological Chemistry, 2012, 287, 25139-25150.	3.4	44
58	Physical imaging phantoms for simulation of tumor heterogeneity in PET, CT, and MRI: An overview of existing designs. Medical Physics, 2020, 47, 2023-2037.	3.0	44
59	The future of hybrid imaging—part 1: hybrid imaging technologies and SPECT/CT. Insights Into Imaging, 2011, 2, 161-169.	3.4	43
60	Optimized contrast-enhanced CT protocols for diagnostic whole-body 18F-FDG PET/CT: technical aspects of single-phase versus multiphase CT imaging. Journal of Nuclear Medicine, 2006, 47, 470-6.	5.0	43
61	PET/MR imaging of the pelvis in the presence of endoprostheses: reducing image artifacts and increasing accuracy through inpainting. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 594-601.	6.4	42
62	Impact of incorrect tissue classification in Dixon-based MR-AC: fat-water tissue inversion. EJNMMI Physics, 2014, 1, 101.	2.7	42
63	Towards quantitative [18F]FDG-PET/MRI of the brain: Automated MR-driven calculation of an image-derived input function for the non-invasive determination of cerebral glucose metabolic rates. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1516-1530.	4.3	42
64	Assessment of attenuation correction for myocardial PET imaging using combined PET/MRI. Journal of Nuclear Cardiology, 2019, 26, 1107-1118.	2.1	42
65	Putting â€~clear' into nuclear medicine: a decade of PET/CT development. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 857-861.	6.4	40
66	Association Between Osteogenesis and Inflammation During the Progression of Calcified Plaque Evaluated by ¹⁸ F-Fluoride and ¹⁸ F-FDG. Journal of Nuclear Medicine, 2017, 58, 968-974.	5.0	40
67	On the use of positioning aids to reduce misregistration in the head and neck in whole-body PET/CT studies. Journal of Nuclear Medicine, 2005, 46, 596-602.	5.0	40
68	Technical and instrumentational foundations of PET/MRI. European Journal of Radiology, 2017, 94, A3-A13.	2.6	39
69	Combined PET/MR: Where Are We Now? Summary Report of the Second International Workshop on PET/MR Imaging April 8–12, 2013, Tubingen, Germany. Molecular Imaging and Biology, 2014, 16, 295-310.	2.6	38
70	Quantitative assessment of atherosclerotic plaques on 18F-FDG PET/MRI: comparison with a PET/CT hybrid system. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1503-1512.	6.4	38
71	The effect of patient positioning aids on PET quantification in PET/MR imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 920-929.	6.4	35
72	Variations in PET/MRI Operations: Results from an International Survey Among 39 Active Sites. Journal of Nuclear Medicine, 2016, 57, 2016-2021.	5.0	35

#	Article	IF	CITATIONS
73	What scans we will read: imaging instrumentation trends in clinical oncology. Cancer Imaging, 2020, 20, 38.	2.8	35
74	High throughput static and dynamic small animal imaging using clinical PET/CT: potential preclinical applications. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 991-1001.	6.4	34
75	Breast Tumor Characterization Using [18F]FDG-PET/CT Imaging Combined with Data Preprocessing and Radiomics. Cancers, 2021, 13, 1249.	3.7	32
76	Effect of MR contrast agents on quantitative accuracy of PET in combined whole-body PET/MR imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1756-1766.	6.4	31
77	Variation of system performance, quality control standards and adherence to international FDG-PET/CT imaging guidelines. Nuklearmedizin - NuclearMedicine, 2014, 53, 242-248.	0.7	31
78	Hybrid Imaging: Instrumentation and Data Processing. Frontiers in Physics, 2018, 6, .	2.1	30
79	Partial volume correction for improved PET quantification in 18F-NaF imaging of atherosclerotic plaques. Journal of Nuclear Cardiology, 2018, 25, 1742-1756.	2.1	29
80	Combined PET/MR Imaging Using 68Ga-DOTATOC for Radiotherapy Treatment Planning in Meningioma Patients. Recent Results in Cancer Research, 2013, 194, 425-439.	1.8	28
81	Radiation exposure levels of routine SPECT/CT imaging protocols. European Journal of Radiology, 2016, 85, 1627-1636.	2.6	28
82	PET/MRI for Oncologic Brain Imaging: A Comparison of Standard MR-Based Attenuation Corrections with a Model-Based Approach for the Siemens mMR PET/MR System. Journal of Nuclear Medicine, 2017, 58, 1519-1525.	5.0	27
83	PET Versus PET/CT Dual-Modality Imaging in Evaluation of Lung Cancer. Radiologic Clinics of North America, 2007, 45, 639-644.	1.8	26
84	Multiphase contrast-enhanced CT with highly concentrated contrast agent can be used for PET attenuation correction in integrated PET/CT imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 316-325.	6.4	26
85	Conditional Generative Adversarial Networks Aided Motion Correction of Dynamic ¹⁸ F-FDG PET Brain Studies. Journal of Nuclear Medicine, 2021, 62, 871-879.	5.0	26
86	Data-driven, projection-based respiratory motion compensation of PET data for cardiac PET/CT and PET/MR imaging. Journal of Nuclear Cardiology, 2020, 27, 2216-2230.	2.1	25
87	The ECAT ART Scanner for Positron Emission Tomography 1. Improvements in Performance Characteristics. Molecular Imaging and Biology, 1999, 2, 5-15.	0.3	24
88	European multicentre study on technical success and long-term clinical outcome of radiofrequency ablation for the treatment of spinal osteoid osteomas and osteoblastomas. Neuroradiology, 2019, 61, 935-942.	2.2	24
89	Personalizing Medicine Through Hybrid Imaging and Medical Big Data Analysis. Frontiers in Physics, 2018, 6, .	2.1	22
90	Whole-body PET/CT imaging: Combining software- and hardware-based co-registration. Zeitschrift Fur Medizinische Physik, 2008, 18, 59-66.	1.5	21

#	Article	IF	CITATIONS
91	Utility of Absolute Quantification in Non-lesional Extratemporal Lobe Epilepsy Using FDG PET/MR Imaging. Frontiers in Neurology, 2020, 11, 54.	2.4	21
92	The use of X-ray CT for attenuation correction of PET data. , 0, , .		20
93	Whole-Body [18F]-FDC-PET/MRI for Oncology: A Consensus Recommendation. Nuklearmedizin - NuclearMedicine, 2019, 58, 68-76.	0.7	20
94	PET/CT is a cost-effective tool against cancer: synergy supersedes singularity. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1749-1752.	6.4	19
95	Dental artifacts in the head and neck region: implications for Dixon-based attenuation correction in PET/MR. EJNMMI Physics, 2015, 2, 8.	2.7	18
96	PET and MRI: Is the Whole Greater than the Sum of Its Parts?. Cancer Research, 2016, 76, 6163-6166.	0.9	18
97	Reproducibility of MRI Dixon-Based Attenuation Correction in Combined PET/MR with Applications for Lean Body Mass Estimation. Journal of Nuclear Medicine, 2016, 57, 1096-1101.	5.0	18
98	Reducing Radiation Exposure to Paediatric Patients Undergoing [18F]FDG-PET/CT Imaging. Molecular Imaging and Biology, 2021, 23, 775-786.	2.6	17
99	Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2 m(1) antibody. MAbs, 2013, 5, 936-945.	5.2	16
100	PET Versus PET/CT Dual-Modality Imaging in Evaluation of Lung Cancer. Thoracic Surgery Clinics, 2010, 20, 25-30.	1.0	15
101	EJNMMI Physics - an editor's perspective. EJNMMI Physics, 2014, 1, 1.	2.7	15
102	Technical Note: Fullyâ€automated analysis of Jaszczak phantom measurements as part of routine <scp>SPECT</scp> quality control. Medical Physics, 2017, 44, 1638-1645.	3.0	15
103	Impact of motion compensation and partial volume correction for ¹⁸ F-NaF PET/CT imaging of coronary plaque. Physics in Medicine and Biology, 2018, 63, 015005.	3.0	15
104	Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2019, 191, 289-297.	1.3	15
105	Promise of Fully Integrated PET/MRI: Noninvasive Clinical Quantification of Cerebral Glucose Metabolism. Journal of Nuclear Medicine, 2020, 61, 276-284.	5.0	15
106	State-of-the-art SPECT/CT: technology, methodology and applications—defining a new role for an undervalued multimodality imaging technique. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1-2.	6.4	14
107	Variations of clinical SPECT/CT operations. Nuklearmedizin - NuclearMedicine, 2012, 51, 154-160.	0.7	12
108	A head coil system with an integrated orbiting transmission point source mechanism for attenuation correction in PET/MRI. Physics in Medicine and Biology, 2018, 63, 225014.	3.0	12

#	Article	IF	CITATIONS
109	Clinically Valuable Quality Control for PET/MRI Systems: Consensus Recommendation From the HYBRID Consortium. Frontiers in Physics, 2019, 7, .	2.1	12
110	Potentials and caveats of AI in hybrid imaging. Methods, 2021, 188, 4-19.	3.8	12
111	Combined PET/CT imaging using a single, dual-modality tomograph: a promising approach to clinical oncology of the future. , 2000, , 101-123.		12
112	MR/PET or PET/MRI: does it matter?. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2013, 26, 1-4.	2.0	11
113	An international survey on hybrid imaging: do technology advances preempt our training and education efforts?. Cancer Imaging, 2018, 18, 15.	2.8	11
114	Nuclear medicine innovations help (drive) healthcare (benefits). European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 173-175.	6.4	10
115	MR–Consistent Simultaneous Reconstruction of Attenuation and Activity for Non–TOF PET/MR. IEEE Transactions on Nuclear Science, 2016, 63, 2443-2451.	2.0	10
116	Impact of intensity discretization on textural indices of [¹⁸ F]FDG-PET tumour heterogeneity in lung cancer patients. Physics in Medicine and Biology, 2019, 64, 125016.	3.0	10
117	Fully Integrated PET/MR Imaging for the Assessment of the Relationship Between Functional Connectivity and Glucose Metabolic Rate. Frontiers in Neuroscience, 2020, 14, 252.	2.8	10
118	The ECAT ART Scanner for Positron Emission Tomography 2. Research and Clinical Applications. Molecular Imaging and Biology, 1999, 2, 17-30.	0.3	9
119	Quantification accuracy of neuro-oncology PET data as a function of emission scan duration in PET/MR compared to PET/CT. European Journal of Radiology, 2017, 95, 257-264.	2.6	9
120	Applied Systems Biology—embracing molecular imaging for systemic medicine. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2721-2725.	6.4	9
121	Automatic correction of dental artifacts in PET/MRI. Journal of Medical Imaging, 2015, 2, 024009.	1.5	8
122	Reproducibility of Quantitative Brain Imaging Using a PET-Only and a Combined PET/MR System. Frontiers in Neuroscience, 2017, 11, 396.	2.8	8
123	Preparing data for multiparametric PET/MR imaging: Influence of PET point spread function modelling and EPI distortion correction on the spatial correlation of [18F]FDG-PET and diffusion-weighted MRI in head and neck cancer. Physica Medica, 2019, 61, 1-7.	0.7	8
124	An International Survey on Clinical Reporting of PET/CT Examinations: A Starting Point for Cross-Specialty Engagement. Journal of Nuclear Medicine, 2019, 60, 480-485.	5.0	8
125	Dynamic [18F]FET-PET/MRI using standard MRI-based attenuation correction methods. European Radiology, 2019, 29, 4276-4285.	4.5	8
126	Standard MRI-based attenuation correction for PET/MRI phantoms: a novel concept using MRI-visible polymer. EJNMMI Physics, 2021, 8, 18.	2.7	8

#	Article	IF	CITATIONS
127	Combined 18F-FDG-PET/CT imaging of the head and neck. An approach to metal artifact correction. Nuklearmedizin - NuclearMedicine, 2006, 45, 219-22.	0.7	8
128	Contrast-Enhanced Dark Lumen PET/CT and MR Colonography in a Rodent Polyp Model: Initial Results with Histopathologic Correlation. American Journal of Roentgenology, 2005, 185, 1045-1047.	2.2	7
129	PET/MRI—knocking on the doors of the rich and famous. British Journal of Radiology, 2017, 90, 20170347.	2.2	7
130	Combined PET/CT for IMRT treatment planning of NSCLC: Contrast-enhanced CT images for Monte Carlo dose calculation. Physica Medica, 2013, 29, 644-649.	0.7	6
131	In Patients We Trust: Reliability of Self-Reported Weight and Height in Nuclear Medicine Patients. Journal of Nuclear Medicine Technology, 2019, 47, 133-136.	0.8	6
132	Quantitative PET/MR imaging of lung cancer in the presence of artifacts in the MR-based attenuation correction maps. Acta Radiologica, 2020, 61, 11-20.	1.1	6
133	Assessment of left and right ventricular functional parameters using dynamic dual-tracer [13N]NH3 and [18F]FDG PET/MRI. Journal of Nuclear Cardiology, 2022, 29, 1003-1017.	2.1	6
134	Lesion Detection and Administered Activity. Journal of Nuclear Medicine, 2020, 61, 1406-1410.	5.0	6
135	Implementation of a Spatially-Variant and Tissue-Dependent Positron Range Correction for PET/CT Imaging. Frontiers in Physiology, 2022, 13, 818463.	2.8	6
136	PET/MRI in the Presurgical Evaluation of Patients with Epilepsy: A Concordance Analysis. Biomedicines, 2022, 10, 949.	3.2	6
137	Improving perceptions of the quality of service in nuclear medicine. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 472-472.	6.4	5
138	Design, Implementation, and Evaluation of a Head and Neck MRI RF Array Integrated with a 511 keV Transmission Source for Attenuation Correction in PET/MR. Sensors, 2019, 19, 3297.	3.8	5
139	Attenuation Correction Approaches for Serotonin Transporter Quantification With PET/MRI. Frontiers in Physiology, 2019, 10, 1422.	2.8	5
140	PI-RADS 2.1 – Image Interpretation: The Most Important Updates andÂTheir Clinical Implications. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2020, 193, 787-796.	1.3	5
141	Medical Physics and Imaging–A Timely Perspective. Frontiers in Physics, 2021, 9, .	2.1	5
142	Image Distortions in Clinical PET/MR Imaging. , 2014, , 21-41.		5
143	Diagnostic Reference Levels for nuclear medicine imaging in Austria: A nationwide survey of used dose levels for adult patients. Zeitschrift Fur Medizinische Physik, 2022, 32, 283-295.	1.5	5
144	Is conflict of interest in our best interest?. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1063-1068.	6.4	4

#	Article	IF	CITATIONS
145	Advancing Biomarker Development Through Convergent Engagement: Summary Report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics; March 14–16, 2018; Vienna, Austria. Molecular Imaging and Biology, 2020, 22, 47-65.	2.6	4
146	20 Years of PET/CT: A Conversation with David Townsend and Thomas Beyer. Journal of Nuclear Medicine, 2020, 61, 1541-1543.	5.0	4
147	Multi-modality imaging of uveal melanomas using combined PET/CT, high-resolution PET and MR imaging. Nuklearmedizin - NuclearMedicine, 2008, 47, 73-9.	0.7	4
148	Development of anthropomorphic mathematical phantoms for simulations of clinical cases in diagnostic nuclear medicine. Computer Methods in Biomechanics and Biomedical Engineering: Imaging and Visualization, 2023, 11, 433-441.	1.9	4
149	Nuclear medicine 2013: from status quo to status go. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1794-1796.	6.4	3
150	Geometric distortions of diffusion weighted imaging of the head/neck in combined PET/MR: optimization of image acquisition and post-processing correction for oncology applications. EJNMMI Physics, 2014, 1, A76.	2.7	3
151	Life is not black and white, nor just Shades of Gray. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 816-821.	6.4	3
152	A new model for training in hybrid imaging. Lancet Oncology, The, 2018, 19, 1152-1154.	10.7	3
153	Accuracy of PET quantification in [68Ga]Ga-pentixafor PET/MR imaging of carotid plaques. Journal of Nuclear Cardiology, 2022, 29, 492-502.	2.1	3
154	Fuzzy Radiomics: A novel approach to minimize the effects of target delineation on radiomic models. Nuklearmedizin - NuclearMedicine, 2019, 58, .	0.7	3
155	Technical note: A PET/MR coil with an integrated, orbiting 511ÂkeV transmission source for PET/MR imaging validated in an animal study. Medical Physics, 2022, 49, 2366-2372.	3.0	3
156	EJNMMI Physics—Access is open for open access. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 197-198.	6.4	2
157	Attitudes and Knowledge Regarding Postmortem Cornea Donation among Young and Elderly People in Germany: Sufficient for Decision Making?. Ophthalmic Research, 2019, 62, 173-184.	1.9	2
158	State of affairs of hybrid imaging in Europe: two multi-national surveys from 2017. Insights Into Imaging, 2019, 10, 57.	3.4	2
159	Dual-Modality PET/CT Acquisition Systems for Clinical Oncology. , 2004, , 9-28.		2
160	Towards truly integrated hardware fusion with PET/CT. Nuklearmedizin - NuclearMedicine, 2005, 44 Suppl 1, S5-12.	0.7	2
161	Anato-Molecular Imaging: Combining Structure and Function. , 2005, , 179-202.		1
162	PET Versus PET/CT Dual-Modality Imaging in Evaluation of Lung Cancer. PET Clinics, 2006, 1, 347-352.	3.0	1

#	Article	IF	CITATIONS
163	Evaluation of PET image quality and distortions in simultaneous clinical PET/MR. , 2012, , .		1
164	Correction of dental artifacts within the anatomical surface in PET/MRI using active shape models and k-nearest-neighbors. Proceedings of SPIE, 2014, , .	0.8	1
165	Intravenous contrast-enhanced CT can be used for CT-based attenuation correction in clinical 111In-octreotide SPECT/CT. EJNMMI Physics, 2015, 2, 3.	2.7	1
166	Simultaneous reconstruction of attenuation and activity for non–TOF PET/MR using MR prior information. EJNMMI Physics, 2015, 2, A30.	2.7	1
167	Physikalisch-technische Grundlagen. , 2016, , 5-34.		1
168	1 + 1 = 3. Nuklearmedizin - NuclearMedicine, 2005, 44 Suppl 1, S1.	0.7	1
169	Reconstruction of 3D whole-body PET data using blurred anatomical labels. , 0, , .		0
170	MR-based Attenuation Correction for PET/MR. Series in Medical Physics and Biomedical Engineering, 2012, , 217-239.	0.1	0
171	Saving costs in cancer patient management through molecular imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2153-2157.	6.4	Ο
172	Local statistical regularization method for solving image reconstruction problems in emission Tomography with Poisson data. AIP Conference Proceedings, 2021, , .	0.4	0
173	Leadership in Medicine, Industry, and Innovation: A Conversation Between Jörg F. Debatin and Thomas Beyer. Journal of Nuclear Medicine, 2021, 62, 435-437.	5.0	Ο
174	Physik/Technik. , 2011, , 7-34.		0
175	PET/MR Instrumentation. , 2013, , 7-28.		Ο
176	PET/CT. Imaging in Medical Diagnosis and Therapy, 2017, , 339-368.	0.0	0
177	Comparison of machine learning-driven lesion classifiers in prostate PET/MRI cases over different repeatability categories of radiomic features. , 2019, 58, .		Ο
178	Inter-site variability of quality control procedures and NEMA image quality in PET/MRI systems. , 2019, 58, .		0
179	Evaluation of tissue-dependent and spatially-variant positron-range correction for Iodine-124 PET/MR data. Nuklearmedizin - NuclearMedicine, 2020, 59, .	0.7	0
180	Assessment of the prompt gamma coincidence correction approach using I-124: a phantom study. , 2020, 59, .		0

#	Article	IF	CITATIONS
181	Understanding gender pattern differences in MET-PET Glioma patients with radiomics analysis. Nuklearmedizin - NuclearMedicine, 2020, 59, .	0.7	0
182	in vivo D'Amico score for low-high risk and biochemical recurrence prediction in prostate patients with PET/MRI and machine learning. , 2020, 59, .		0
183	A simple multi-modality phantom for simulating radiomic features in PET, CT and MRI. Nuklearmedizin - NuclearMedicine, 2020, 59, .	0.7	0
184	Reducing [18 F]FDG activity levels for whole-body PET/CT examinations of children. , 2020, 59, .		0
185	GATE Monte Carlo simulation model of the Symbia Intevo SPECT/CT system. Nuklearmedizin - NuclearMedicine, 2020, 59, .	0.7	0
186	Parameterisation of Positron Range Effects in PET/MRI. Nuklearmedizin - NuclearMedicine, 2020, 59, .	0.7	0
187	A Conversation Between Yasuhito Sasaki and Thomas Beyer. Journal of Nuclear Medicine, 2020, 61, 940-942.	5.0	0
188	Evaluation of different positron range correction implementations in iterative image reconstruction for I-124 PET imaging. Nuklearmedizin - NuclearMedicine, 2022, 61, .	0.7	0
189	Additively manufactured, solid object structures for adjustable image contrast in Magnetic Resonance Imaging. Zeitschrift Fur Medizinische Physik, 2022, 32, 466-476.	1.5	О